**California voters will decide Proposition 38 on November 3, 2026, which would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, split evenly between grants to public and nonprofit institutions and a single UC-affiliated research institute selected by the Department of Public Health, with half the funds directed to cancer, heart disease, and Alzheimer’s work.** The measure carries an estimated $500–600 million annual General Fund repayment cost for roughly 20–25 years, offset only partially by potential future royalties or licensing revenue. Opposition has centered on the added long-term debt burden, the earmark for one predetermined-style recipient, and questions about administrative controls and pricing mandates. These fiscal and structural concerns appear to underpin the current trader consensus favoring rejection, even as disease advocacy groups continue to promote the initiative as a state-level response to federal research funding pressures.